<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/40DAEA31-C854-4F39-BDD3-E0822A3C4AFB"><gtr:id>40DAEA31-C854-4F39-BDD3-E0822A3C4AFB</gtr:id><gtr:name>Foundation for Research and Technology Hellas (FORTH)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/975A9F33-3873-423C-AADB-77257FFD8C25"><gtr:id>975A9F33-3873-423C-AADB-77257FFD8C25</gtr:id><gtr:name>Aga Khan University</gtr:name><gtr:address><gtr:line1>Stadium Road</gtr:line1><gtr:line2>PO Box 3500</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C6BF93FE-5C2F-472A-B6FC-00A9E38121DB"><gtr:id>C6BF93FE-5C2F-472A-B6FC-00A9E38121DB</gtr:id><gtr:name>School of Public Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EA2F440C-6AAD-4698-BDE9-27F559BDB96E"><gtr:id>EA2F440C-6AAD-4698-BDE9-27F559BDB96E</gtr:id><gtr:name>School of Medical Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F11E21C9-E05F-4173-939C-61F868FE1FBA"><gtr:id>F11E21C9-E05F-4173-939C-61F868FE1FBA</gtr:id><gtr:name>The Wellcome Trust Ltd</gtr:name><gtr:address><gtr:line1>215 Euston Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW1 2BE</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/40DAEA31-C854-4F39-BDD3-E0822A3C4AFB"><gtr:id>40DAEA31-C854-4F39-BDD3-E0822A3C4AFB</gtr:id><gtr:name>Foundation for Research and Technology Hellas (FORTH)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/47CC4050-87A9-4965-B949-35C9C52402DA"><gtr:id>47CC4050-87A9-4965-B949-35C9C52402DA</gtr:id><gtr:name>Pharmidex</gtr:name><gtr:address><gtr:line1>Pharmidex</gtr:line1><gtr:line2>72 New Bond Street</gtr:line2><gtr:line3>Mayfair</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>W15 1RR</gtr:postCode><gtr:region>Unknown</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/975A9F33-3873-423C-AADB-77257FFD8C25"><gtr:id>975A9F33-3873-423C-AADB-77257FFD8C25</gtr:id><gtr:name>Aga Khan University</gtr:name><gtr:address><gtr:line1>Stadium Road</gtr:line1><gtr:line2>PO Box 3500</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C6BF93FE-5C2F-472A-B6FC-00A9E38121DB"><gtr:id>C6BF93FE-5C2F-472A-B6FC-00A9E38121DB</gtr:id><gtr:name>School of Public Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8BFE03FB-6AF2-46C4-942E-1262EFD09774"><gtr:id>8BFE03FB-6AF2-46C4-942E-1262EFD09774</gtr:id><gtr:name>Royal Free London NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Pond Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>NW3 2QG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EA2F440C-6AAD-4698-BDE9-27F559BDB96E"><gtr:id>EA2F440C-6AAD-4698-BDE9-27F559BDB96E</gtr:id><gtr:name>School of Medical Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/621CACAB-53EE-48C8-A5EF-69DA4FA58943"><gtr:id>621CACAB-53EE-48C8-A5EF-69DA4FA58943</gtr:id><gtr:name>Leibniz Association</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3906539B-C036-4768-81DF-2C50AC12265A"><gtr:id>3906539B-C036-4768-81DF-2C50AC12265A</gtr:id><gtr:firstName>Theresa</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:orcidId>0000-0002-9881-8649</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400373"><gtr:id>8CB86B2B-82FC-4670-ABD6-290120A3ACE0</gtr:id><gtr:title>Components required for ER exit site assembly in generic cell lines, and during B lymphocyte activation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400373</gtr:grantReference><gtr:abstractText>Antibodies form a major line of defense in the body?s fight against infectious disease. When the body reacts against a disease-causing organism, some of the white blood cells turn into antibody-producing factories, a process which involves major changes within the cells. We want to investigate how this happens, looking at the processes involved in live cells through innovative microscopy techniques. Jellyfish green fluorescent protein has become one of the most popular tools for cell biologists for the study of dynamic processes inside living cells by enabling direct tagging of proteins normally found inside cells. We now wish to label different steps involved in antibody production with fluorescent proteins, to investigate how the cell changes and how the antibodies are then directed out of the cell along the cell?s so-called secretory pathway, into the bloodstream. By understanding the mechanisms involved in normal, healthy cells, we hope to apply the knowledge to human diseases attributable to these white blood cells and malfunction of their secretion, such as arthritis where some cells lose control of antibody production, or Burkitt?s lymphoma, a cancer prevalent in African children, caused by infection by Epstein-Barr virus which piggy-backs on the cell?s secretory system.</gtr:abstractText><gtr:technicalSummary>To form a crucial line of defence against infectious diseases, activated B cells differentiate into plasma cells. These are efficient cellular factories dedicated to the production and secretion of antibodies into the bloodstream. At the ultrastructural level, plasma cells are characterised by a massive proliferation of the endoplasmic reticulum (ER), the first organelle in the secretory pathway. The mechanisms underlying this morphogenesis are unknown. The major aim of this project will be to define the changes that take place in the cell?s secretory pathway upon B cell activation and how the cell copes with such an increased secretory burden at the level of ER exit. In a complementary approach, the mechanisms by which ER exit sites assemble and associate with microtubules will be investigated in basic adherent cell lines. By using live-cell imaging techniques, such as time-lapse imaging, dual colour labelling, photobleaching approaches, and fluorescence correlation spectroscopy (FCS), applied to a combination of GFP chimaeras of secretory pathway and cargo components, we will be able to visualise and analyse these events in real time. Many human diseases are based on misfunction of the secretory pathway and comprehending the basic cell biology will aid understanding and potentially treatment or prevention of their pathobiology. In particular, knowledge of B cell differentiation and plasma cell biology will have direct relevance to clinical areas of research such as arthritis characterised by accumulation of antibody-producing plasma cells in patients? joints, as well as autoimmune-related cancers such as Burkitt?s lymphoma.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>239527</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Clinical Sciences Centre (CSC)</gtr:department><gtr:description>Multiple myeloma</gtr:description><gtr:id>D000A25D-7F20-4170-91F7-04CA3F5547EE</gtr:id><gtr:impact>This collaboration has resulted in a successful clinical fellowship application, a current project grant application, and a recently published manuscript (PMID:24069311 ). The project also has more translational clinical links than my original basic cell biological research.</gtr:impact><gtr:partnerContribution>The collaborator has provided new tools/reagents for my research.</gtr:partnerContribution><gtr:piContribution>Assistance in setting up assays developed in my research team, providing reagents and imaging expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Infectious and Tropical Diseases</gtr:department><gtr:description>Wellcome - Chagas</gtr:description><gtr:id>A7B1C1EF-EC76-4915-A250-7D9500547613</gtr:id><gtr:impact>We have received a project grant from the Wellcome Trust to establish an in vivo imaging model to follow the pathogenesis and treatment of Trypanosoma cruzi, the causative agent of Chagas disease.</gtr:impact><gtr:partnerContribution>Leading the research into T. cruzi pathogenesis and treatment</gtr:partnerContribution><gtr:piContribution>Fluorescent protein and imaging expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Veterinary Medicine and Science Nottingham</gtr:department><gtr:description>Ecoli K1</gtr:description><gtr:id>B09E4D7A-E6FE-4551-962F-FDECF36F9366</gtr:id><gtr:impact>I was awarded studentship funding from the Bloomsbury Colleges and funding from the University of London Central Research Fund. This work has led to a Methods paper (PMID:22341221) and another paper under submission, and currently two research grants are under review.</gtr:impact><gtr:partnerContribution>The collaborator provided expertise and reagents for work on E. coli K1.</gtr:partnerContribution><gtr:piContribution>I provide equipment and microscopy expertise, and developed cell biology assays for K1 infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Aga Khan University, Karachi</gtr:collaboratingOrganisation><gtr:country>Pakistan, Islamic Republic of</gtr:country><gtr:description>Ecoli K1</gtr:description><gtr:id>A64D0E0D-A4D6-467C-B151-D0B62DAAA7BF</gtr:id><gtr:impact>I was awarded studentship funding from the Bloomsbury Colleges and funding from the University of London Central Research Fund. This work has led to a Methods paper (PMID:22341221) and another paper under submission, and currently two research grants are under review.</gtr:impact><gtr:partnerContribution>The collaborator provided expertise and reagents for work on E. coli K1.</gtr:partnerContribution><gtr:piContribution>I provide equipment and microscopy expertise, and developed cell biology assays for K1 infection.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free London NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Royal Free Hospital</gtr:department><gtr:description>EBV-Royal Free</gtr:description><gtr:id>E343A1B9-E862-4833-B760-46898A5E59A1</gtr:id><gtr:impact>I obtained funding for a studentship from the Pathological Society to investigate the cell biology of EBV infection of B cells. Currently a project grant proposal has been submitted to pursue this research.</gtr:impact><gtr:partnerContribution>A consultant virologist with expertise in EBV, a virus specific to B cells, has provided reagents, equipment access, and intellectual input to the research.</gtr:partnerContribution><gtr:piContribution>I provide the expertise in B cell biology and microscopy techniques.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Heart,?Lung, and?Blood Institute?(NHLBI)</gtr:department><gtr:description>B cell differentiation</gtr:description><gtr:id>794C9A79-5DEE-43A3-AB9E-5F153E0AB1DF</gtr:id><gtr:impact>It is too early for any outputs at this stage.</gtr:impact><gtr:partnerContribution>My partners are hosting my sabbatical visit, where we are testing various new assays to apply to B cell differentiation.</gtr:partnerContribution><gtr:piContribution>B cell expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Public Health</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Infectious Disease &amp; Epidemiology</gtr:department><gtr:description>Gates - Tuberculosis</gtr:description><gtr:id>424C797A-5BC1-4121-A51C-F491418B6499</gtr:id><gtr:impact>We received funding from the Bill &amp;amp; Melinda Gates Foundation for $4.5 million to develop the in vivo imaging model. This has resulted in 2 publications in 2010 (PMID: 20520722, 20352111), one in 2012 (PMID:22635525), one in 2013 (PMID:23841905). The project is multidisciplinary, requiring microbiological expertise to develop the bacterial strains, immunology of the animal models, cell biology and imaging expertise of the biological models, and physics for the development of the imaging instrumentation (the FMT).</gtr:impact><gtr:partnerContribution>Leader of a multi-disciplined consortium to establish an in vivo imaging model of tuberculosis to facilitate drug testing. The development of fluorescent tuberculosis strains. The development of bioluminescent Mtb reporters. The development of a new in vivo imaging system that we are using to detect fluorescent Tb in the model. Expertise on in vivo imaging of bioluminescent organisms.</gtr:partnerContribution><gtr:piContribution>Fluorescent protein and imaging expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leibniz Association</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Leibniz Center for Medicine and Biosciences</gtr:department><gtr:description>Gates - Tuberculosis</gtr:description><gtr:id>A7E46FFB-90F4-48D9-9BAC-E3725559C594</gtr:id><gtr:impact>We received funding from the Bill &amp;amp; Melinda Gates Foundation for $4.5 million to develop the in vivo imaging model. This has resulted in 2 publications in 2010 (PMID: 20520722, 20352111), one in 2012 (PMID:22635525), one in 2013 (PMID:23841905). The project is multidisciplinary, requiring microbiological expertise to develop the bacterial strains, immunology of the animal models, cell biology and imaging expertise of the biological models, and physics for the development of the imaging instrumentation (the FMT).</gtr:impact><gtr:partnerContribution>Leader of a multi-disciplined consortium to establish an in vivo imaging model of tuberculosis to facilitate drug testing. The development of fluorescent tuberculosis strains. The development of bioluminescent Mtb reporters. The development of a new in vivo imaging system that we are using to detect fluorescent Tb in the model. Expertise on in vivo imaging of bioluminescent organisms.</gtr:partnerContribution><gtr:piContribution>Fluorescent protein and imaging expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London (QMUL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>Gates - Tuberculosis</gtr:description><gtr:id>5C82F513-2BF4-4212-BA20-7A9EA6BE0FEB</gtr:id><gtr:impact>We received funding from the Bill &amp;amp; Melinda Gates Foundation for $4.5 million to develop the in vivo imaging model. This has resulted in 2 publications in 2010 (PMID: 20520722, 20352111), one in 2012 (PMID:22635525), one in 2013 (PMID:23841905). The project is multidisciplinary, requiring microbiological expertise to develop the bacterial strains, immunology of the animal models, cell biology and imaging expertise of the biological models, and physics for the development of the imaging instrumentation (the FMT).</gtr:impact><gtr:partnerContribution>Leader of a multi-disciplined consortium to establish an in vivo imaging model of tuberculosis to facilitate drug testing. The development of fluorescent tuberculosis strains. The development of bioluminescent Mtb reporters. The development of a new in vivo imaging system that we are using to detect fluorescent Tb in the model. Expertise on in vivo imaging of bioluminescent organisms.</gtr:partnerContribution><gtr:piContribution>Fluorescent protein and imaging expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Centre for Molecular Parasitology</gtr:department><gtr:description>Gates - human sleeping sickness</gtr:description><gtr:id>519F796B-996F-47E0-8128-3C083C4FFB4E</gtr:id><gtr:impact>The LSHTM group and the Glasgow group obtained $3 million from the Bill &amp;amp; Melinda Gates Foundation to establish an in vivo imaging model for human African trypanosomiasis to enable downstream drug screening. This is a multi-disciplinary project involving many different imaging modalities (MRI, bioluminescent and fluorescent whole animal imaging, and multiphoton microscopy), molecular biology to manipulate the parasites, immunology of the animal infection model and pharmacology approaches (PK/PD and microdialysis) to test prospective compounds. We have a first publication in press and a one year extension to roll out a robust drug-screening model to interested commercial parties.</gtr:impact><gtr:partnerContribution>Consortium leader and members of several departments at Glasgow are involved in different aspects of the researchPharmidex are providing the microdialysis model to follow activity of drugs in the CNS</gtr:partnerContribution><gtr:piContribution>Fuorescent protein and imaging expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medical Sciences</gtr:collaboratingOrganisation><gtr:country>New Zealand</gtr:country><gtr:department>Department of Molecular Medicine and Pathology (MMP)</gtr:department><gtr:description>Gates - Tuberculosis</gtr:description><gtr:id>3C5CF913-B7C6-47AF-AB3A-A8B18CBBA448</gtr:id><gtr:impact>We received funding from the Bill &amp;amp; Melinda Gates Foundation for $4.5 million to develop the in vivo imaging model. This has resulted in 2 publications in 2010 (PMID: 20520722, 20352111), one in 2012 (PMID:22635525), one in 2013 (PMID:23841905). The project is multidisciplinary, requiring microbiological expertise to develop the bacterial strains, immunology of the animal models, cell biology and imaging expertise of the biological models, and physics for the development of the imaging instrumentation (the FMT).</gtr:impact><gtr:partnerContribution>Leader of a multi-disciplined consortium to establish an in vivo imaging model of tuberculosis to facilitate drug testing. The development of fluorescent tuberculosis strains. The development of bioluminescent Mtb reporters. The development of a new in vivo imaging system that we are using to detect fluorescent Tb in the model. Expertise on in vivo imaging of bioluminescent organisms.</gtr:partnerContribution><gtr:piContribution>Fluorescent protein and imaging expertise</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Foundation for Research and Technology Hellas (FORTH)</gtr:collaboratingOrganisation><gtr:country>Greece, Hellenic Republic</gtr:country><gtr:department>Institute of Electronic Structure and Laser (IESL)</gtr:department><gtr:description>Gates - Tuberculosis</gtr:description><gtr:id>E003723E-E23D-49AA-95D6-5BF10D1A8450</gtr:id><gtr:impact>We received funding from the Bill &amp;amp; Melinda Gates Foundation for $4.5 million to develop the in vivo imaging model. This has resulted in 2 publications in 2010 (PMID: 20520722, 20352111), one in 2012 (PMID:22635525), one in 2013 (PMID:23841905). The project is multidisciplinary, requiring microbiological expertise to develop the bacterial strains, immunology of the animal models, cell biology and imaging expertise of the biological models, and physics for the development of the imaging instrumentation (the FMT).</gtr:impact><gtr:partnerContribution>Leader of a multi-disciplined consortium to establish an in vivo imaging model of tuberculosis to facilitate drug testing. The development of fluorescent tuberculosis strains. The development of bioluminescent Mtb reporters. The development of a new in vivo imaging system that we are using to detect fluorescent Tb in the model. Expertise on in vivo imaging of bioluminescent organisms.</gtr:partnerContribution><gtr:piContribution>Fluorescent protein and imaging expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pharmidex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Gates - human sleeping sickness</gtr:description><gtr:id>47A7B39F-0610-4C32-B4D5-8E357F692719</gtr:id><gtr:impact>The LSHTM group and the Glasgow group obtained $3 million from the Bill &amp;amp; Melinda Gates Foundation to establish an in vivo imaging model for human African trypanosomiasis to enable downstream drug screening. This is a multi-disciplinary project involving many different imaging modalities (MRI, bioluminescent and fluorescent whole animal imaging, and multiphoton microscopy), molecular biology to manipulate the parasites, immunology of the animal infection model and pharmacology approaches (PK/PD and microdialysis) to test prospective compounds. We have a first publication in press and a one year extension to roll out a robust drug-screening model to interested commercial parties.</gtr:impact><gtr:partnerContribution>Consortium leader and members of several departments at Glasgow are involved in different aspects of the researchPharmidex are providing the microdialysis model to follow activity of drugs in the CNS</gtr:partnerContribution><gtr:piContribution>Fuorescent protein and imaging expertise.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>London School of Hygiene and Tropical Medicine (LSHTM)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Bluetongue virus</gtr:description><gtr:id>F4A033A0-CBBE-4D33-991C-E7FD57358950</gtr:id><gtr:impact>This has resulted in a publication (PMID:25142589) and work is ongoing</gtr:impact><gtr:partnerContribution>They provided the reagents</gtr:partnerContribution><gtr:piContribution>Imaging expertise for live virus trafficking</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Provision of teaching aids</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>49C00419-7D66-4B69-99E0-74A52DD16BCC</gtr:id><gtr:impact>Provision of teaching materials to two primary schools, primarily movies of cells fluorescently labelled to demonstrate fundamental behaviour e.g. cell division

No tangible impact</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Port Magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CE10127D-471E-4D95-A4FB-DCDEFCCE481F</gtr:id><gtr:impact>Contribution to a general interest article on scientific research into infectious organisms for a men's magazine

No significant impacts.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nuffield Bursary Scheme</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EAE8C699-9C99-4C8F-BFF3-B5A0C4EC03AE</gtr:id><gtr:impact>Participation in the Nuffield Science Bursary scheme, which enabled a 6th form student to take part in a 4 week research project in my lab.

No tangible impact</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientist-MP Pairing Scheme</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>35349638-844A-4C08-8905-C2A0CB4E49B6</gtr:id><gtr:impact>This gave me the opportunity to speak about my research not only to the MP with whom I was paired (Dr Ian Gibson MP) but also to others at various events held in the Houses of Parliament during the week-long scheme. Further to this I was contacted by the OSI (Office of Science and Innovation) now the DIUS (Department for Innovation, Universities and Skills) at the DTI to discuss various aspects of funding and research as an early career investigator.

No tangible impact.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Learning Zone</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE64CE3E-5296-41C3-8823-08CB955ABF89</gtr:id><gtr:impact>Microscience is a microscopy exhibition with a parallel conference attended by industry, public and school groups. The Learning Zone is an area with microscopes set up for demonstration purposes to learn basic techniques or to look at different types of samples and to see more complicated instruments and .

This raised awareness of Microscope Activity Kits available through the RMS for loan to schools, although at present only for primary schools.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>58000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bloomsbury Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>University of London</gtr:fundingOrg><gtr:id>650517B1-DE7F-4AC5-9805-6EC8BAC81ECC</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathological Society PhD Sponsorship Award</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Pathological Society of Great Britain &amp; Ireland</gtr:fundingOrg><gtr:id>1E2B2916-5AD2-495B-BBAB-5C32BBE2E309</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of London Central Research Fund</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>University of London</gtr:fundingOrg><gtr:id>1F625251-41BA-46A0-9DDE-565DC2923D9F</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Bioimaging UK</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B70F84DE-17BC-487C-86AF-0D86D79E23FD</gtr:id><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a semi-automated method of quantitation of area and volume measurements of endoplasmic reticulum and Golgi membranes from electron micrographs.</gtr:description><gtr:id>82C6D9E7-9A4B-4928-99AE-C01784E88C9C</gtr:id><gtr:impact>Another group have used this method to analyse multiple myeloma cells undergoing chemotherapy treatment, recently published</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>organelle quantitation</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed an in vitro terminal differentiation assay for human B lymphocytes to look at the changing molecular requirements in the secretory pathway of B cells as they transition into antibody-secreting plasma cells, a process important for the body to fight infectious diseases.</gtr:description><gtr:id>F9454777-47AF-4556-ADFC-FE4FD3FE1EC0</gtr:id><gtr:impact>At least 3 other groups are using our technique to model differentiation changes in vitro.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>differentiation assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/66010AB9-910A-44DB-B1CB-5B36784D6BD9"><gtr:id>66010AB9-910A-44DB-B1CB-5B36784D6BD9</gtr:id><gtr:title>Golgi inheritance in mammalian cells is mediated through endoplasmic reticulum export activities.</gtr:title><gtr:parentPublicationTitle>Molecular biology of the cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/760d3b5442f8dfb98f3ce7452e45d4a8"><gtr:id>760d3b5442f8dfb98f3ce7452e45d4a8</gtr:id><gtr:otherNames>Altan-Bonnet N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1059-1524</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F75538D7-0EEE-4D81-BF2F-B4B5FE30C37D"><gtr:id>F75538D7-0EEE-4D81-BF2F-B4B5FE30C37D</gtr:id><gtr:title>Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b7b66591a70722ef84d0d2def98a8fa4"><gtr:id>b7b66591a70722ef84d0d2def98a8fa4</gtr:id><gtr:otherNames>Auner HW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CE33B3C-09E7-49B1-9699-D8ABA032E3B3"><gtr:id>1CE33B3C-09E7-49B1-9699-D8ABA032E3B3</gtr:id><gtr:title>Trafficking through the early secretory pathway of mammalian cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d68e3c5fa7398c9006dd3da9e0bfdfb"><gtr:id>4d68e3c5fa7398c9006dd3da9e0bfdfb</gtr:id><gtr:otherNames>Ward TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3695A24F-BCEE-4316-B9F5-1D2434D2AB56"><gtr:id>3695A24F-BCEE-4316-B9F5-1D2434D2AB56</gtr:id><gtr:title>The uses of green fluorescent protein in mammalian cells.</gtr:title><gtr:parentPublicationTitle>Methods of biochemical analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d68e3c5fa7398c9006dd3da9e0bfdfb"><gtr:id>4d68e3c5fa7398c9006dd3da9e0bfdfb</gtr:id><gtr:otherNames>Ward TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0076-6941</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFC0A8F5-1721-4FF7-94F1-CD204C36D31F"><gtr:id>AFC0A8F5-1721-4FF7-94F1-CD204C36D31F</gtr:id><gtr:title>Biogenesis of secretory organelles during B cell differentiation.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d1a7a3e9df6417049f71c446c1f489d"><gtr:id>8d1a7a3e9df6417049f71c446c1f489d</gtr:id><gtr:otherNames>Kirk SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E850B2DE-D016-4D7B-BAD7-66FB96ABB9A2"><gtr:id>E850B2DE-D016-4D7B-BAD7-66FB96ABB9A2</gtr:id><gtr:title>COPII under the microscope.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d1a7a3e9df6417049f71c446c1f489d"><gtr:id>8d1a7a3e9df6417049f71c446c1f489d</gtr:id><gtr:otherNames>Kirk SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400373</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>